| Gene Symbol | ent-gene-3b7e0513 |
| Recombinant enzyme | Cerliponase alfa is produced using a Chinese hamster ovary (CHO) cell expression system, resulting in a human-like enzyme with optimal activity at acidic pH (optimal pH 4.5)[@vuillemenot2015] |
| Substrate clearance | The administered TPP1 enzyme cleaves N-terminal tripeptides from substrate proteins within lysosomes, reducing the accumulation of autofluorescent lipopigments (ceroid and lipofuscin)[@kohan2013] |
| Cellular uptake | The enzyme is internalized by cells through mannose-6-phosphate receptor-mediated endocytosis, ensuring delivery to lysosomes where it exerts its catalytic activity[@urayama2018] |
| Intracerebroventricular delivery | Direct infusion into the cerebrospinal fluid (CSF) of the lateral ventricles bypasses the blood-brain barrier, achieving therapeutic concentrations in brain tissue[@gieselmann2018] |
| Distribution | Studies demonstrate widespread distribution throughout the central nervous system, including the cortex, cerebellum, and deep brain structures[@markham2017] |
| Dosing rationale | The 300 mg dose every 2 weeks was selected based on dose-finding studies showing optimal enzyme activity in CSF with manageable safety profiles[@schulz2019] |
| Clinical presentation | Children present with seizures (often myoclonic), language delay, ataxia, and motor regression[@santorelli2019] |
| Disease progression | Without treatment, most children lose the ability to walk and talk by age 6-8 years, with death typically occurring in the second decade[@mink2020] |
| Treatment benefits | Clinical trials demonstrated that cerliponase alfa significantly slows the rate of motor decline, as measured by the Hamburg Scale and the CLN2 Clinical Rating Scale[@adams2021] |
| Study 1 (NCT01991756) | A randomized, delayed-treatment trial showing 52-week treatment resulted in 80% slower motor decline compared to untreated historical controls[@schulz2020] |
| Study 2 (NCT02485899) | An open-label extension confirming sustained treatment benefits over 3+ years of follow-up[@pierpont2020] |
| Long-term data | Registry data from the CLN2 Disease Registry demonstrate continued treatment benefits with >5 years of cumulative exposure in some patients[@cln2023] |
| Metachromatic leukodystrophy (MLD) | Atlerersen (AT222) is being developed for ARSA deficiency using a similar ICV delivery approach[@biffi2019] |
| Mucopolysaccharidosis I (MPS I) | Idursulfase ICV is under investigation for Hurler syndrome with CNS involvement[@giugliani2018] |
| Pompe disease | Gene therapy and ERT combination approaches are being explored to address both cardiac and CNS manifestations[@byrne2021] |
| KG Connections | 2 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
No AI portrait yet
No comments yet. Be the first to comment!